These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 9888613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
    Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW.
    Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
    Peck RW, Seaber EJ, Dixon R, Gillotin CG, Weatherley BC, Layton G, Posner J.
    Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
    [Abstract] [Full Text] [Related]

  • 5. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.
    Smith DA, Cleary EW, Watkins S, Huffman CS, Polvino WJ.
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):301-5. PubMed ID: 9660035
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
    Martin GR.
    Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ, Ridout G, Layton G, Posner J, Peck RW.
    Eur J Clin Pharmacol; 1997 Oct; 53(3-4):229-34. PubMed ID: 9476036
    [Abstract] [Full Text] [Related]

  • 11. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
    Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL.
    Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
    Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S.
    Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
    [Abstract] [Full Text] [Related]

  • 14. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [Abstract] [Full Text] [Related]

  • 15. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolan PE, Pack RW.
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
    Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM.
    Neurology; 1997 Nov; 49(5):1219-25. PubMed ID: 9371897
    [Abstract] [Full Text] [Related]

  • 17. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J, Sawyer J.
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The clinical pharmacokinetics of zolmitriptan.
    Dixon R, Warrander A.
    Cephalalgia; 1997 Oct; 17 Suppl 18():15-20. PubMed ID: 9399013
    [Abstract] [Full Text] [Related]

  • 20. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
    Dixon RM, Meire HB, Evans DH, Watt H, On N, Posner J, Rolan PE.
    Cephalalgia; 1997 Oct; 17(6):639-46. PubMed ID: 9350383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.